Mark Stroh

Learn More
Neurotrophins such as nerve growth factor (NGF) may be useful for treating diseases in the central nervous system; our ability to harness the potential therapeutic benefit of NGF is directly related to our understanding of the fate of exogenously supplied factors in brain tissue. We utilized multiphoton microscopy to quantify the dynamic behavior of NGF in(More)
Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end(More)
Novae are thermonuclear explosions on a white dwarf surface fueled by mass accreted from a companion star. Current physical models posit that shocked expanding gas from the nova shell can produce x-ray emission, but emission at higher energies has not been widely expected. Here, we report the Fermi Large Area Telescope detection of variable gamma-ray(More)
We present the first systematic investigation of the morphological and timing properties of flares in GRBs observed by Swift/XRT. We consider a large sample drawn from all GRBs detected by Swift, INTEGRAL and HETE-2 prior to 2006 Jan 31, which had an XRT follow-up and which showed significant flaring. Our sample of 33 GRBs includes long and short, at low(More)
Observations of gamma ray bursts (GRBs) with Swift produced the initially surprising result that many bursts have large X-ray flares superimposed on the underlying afterglow. The flares were sometimes intense, had rapid rise and decay phases, and occurred late relative to the " prompt " phase. One remarkable flare was observed by XRT with a flux ≥500× the(More)
The Swift X-ray Telescope (XRT) has discovered that flares are quite common in early X-ray afterglows of gamma-ray bursts (GRBs), being observed in roughly 50% of afterglows with prompt follow-up observations. The flares range in fluence from a few per cent to approximately 100% of the fluence of the prompt emission (the GRB). Repetitive flares are seen,(More)
The maximally tolerated dose (MTD) of cytotoxic agents has historical precedence in treating cancer, as it was believed that dose and therapeutic effect are intrinsically linked and that the MTD would provide greatest therapeutic value. With molecularly targeted agents, the premise of preventing toxicity to normal tissues while modulating tumor growth(More)
The phase III trial comparing onartuzumab + erlotinib vs. erlotinib in the second- and third-line non-small cell lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). The objective was to assess whether doses higher than the phase III dose (15 mg/kg) might yield better efficacy without compromising the safety profile. Data were(More)
Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be(More)
Rolofylline is a potent, selective adenosine A1 receptor antagonist that was under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites (metabolites) by cytochrome P450 (CYP) 3A4. The aim of this investigation(More)